Canadian pharmaceutical company Acerus Pharmaceuticals Corp. announced last week that its contract with Endo Ventures Bermuda Limited to commercialize NATESTO, a testosterone replacement nasal gel, will be terminated effective June 30, 2016.
“While we are disappointed with Endo’s previously announced strategic business decision to realign their U.S. branded resources from urology retail to their pain franchise, we are fully committed to the continued success of NATESTO in the U.S.,” President and CEO of Acerus Tom Rossi said.
Rossi said the company will now seek a new NATESTO partner in the U.S., the largest market for testosterone replacement therapy. “We are encouraged by the positive physician and patient feedback received on the product to date, and believe there will be strong interest from other companies to step in and continue to drive the launch of NATESTO,” he said.
On Thursday, January 7, at 8:30 a.m. EST Acerus will host a conference call to inform investors on the company’s updated business model and priorities for 2016.
To access the call live, dial 416-340-2216 or 1-866-225-2055. Listeners are asked to dial in 10 minutes prior to the start of the conference call.
A recorded replay of the discussion will be available until 11:59 p.m. EST on Tuesday, January 12 by dialing 905-694-9451 or 1-800-408-3053, using access code: 2285177#.